Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pre-surgical study of LEE011 plus letrozole versus letrozole alone in HR-positive HER2-negative breast cancer
NL-OMON40407Phase 2Recruiting
- Sponsor
- Novartis
- Start
- Jan 2014
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of ribociclib, letrozole in breast cancer, sponsored by Novartis. Started Jan 2014; status: recruiting.
02
Drugs
ribociclibletrozole
03
Conditions
breast cancer
Beyond the preview
Go deeper on NL-OMON40407.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON40407.